U.S. Markets close in 2 hrs 57 mins

Rosetta Genomics Ltd. (ROSG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.040-0.490 (-19.372%)
As of 1:00PM EDT. Market open.
People also watch
  • gedy for ascary scary crash crashbelow 1.50 be veryvery af money run run to the exit exit door get ouout beterbesafe than sorry
  • Has anyone tried actually suing this company before, just curious? I'm in on small shares but jeez I have never, ever seen this thing going up. Where are the lawsuits?
  • When, if ever, has a management action resulted in a higher stock price? It seems to me that any rise in share price is an invitation by management to bring it back down.
  • huge dillution back on..maybe gets done under 1. with warrants like 7m new shares....can you say reverse split
  • Rosetta Genomics files for 16.358M offering of Class A, Class B units, Warrants
  • I entered last week with 8000k share from 2.50. Lets see whats gonna happen!
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets


    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.


    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • Reveal is real. I'm a recent investor to ROSG with an average buy-in price of around $2.85 and now have substantial ownership of ROSG.. Both my father and my sister had thyroid surgery because their lab tests came back as "indeterminate". Fortunately both cases were benign ! The point being that Reveal could likely have saved $10,000's to the insurance company.
    This product alone is worth a $40+ million valuation now that its approved and marketed, not to mention all the other IP. ROSG at these price levels is a crazy bargain and someone has figured it out and is accumulating. Last chance to buy at these levels in my opinion!!!
  • Told u so!
  • Kenny selling shares before ER?
  • Michael- We had 7.6 million in January. We should run out of cash by aug. 15 ( assuming same burn rate like last year )
    Hopefullly with some reduction in staff and reveal revenue the fund could last till sept 30.

    If personalized DX is sold it would buy another 6 weeks

    So Mr. Berlin will have some good announcement in July and he will follow that up with ATM. We need to get out before ATM.
  • I predict we will hear about the sale of PersonalizedDx in July or August and it will bring in a lot more money than many of you are expecting - giving the company some very solid non-dilutive funding. I believe there are quite a few entities out there bidding for PersonalizedDex.
  • Told you guys that Reveal is the real deal, but a lot of you aren't listening. Well, some folks are listening, as is evident by the share price climb since May. We are just getting started. Remember, Afirma does $16M in revenues PER quarter. Reveal could get there a few years down the road. Or Veracyte could simply #$%$ up Rosetta, but I hope not, because I believe Rosetta has turned the corner on a tremendous market opportunity.
  • 3 strait days of accumulation and AH/premarket trading... broker has August as the ER
  • can't really fly...all waiting fir dilution headline
  • Peeps are pumping, u have been warned, company is a joke run by a greedy clown!
  • Another accumulation day... Been like this since 1.4.
  • guess. pump is over
  • Lost 85% of my investment in less than 2 years (60,000) yet people say "butt hurt bag holders" yes it hurts, yes I sold, it would have to go up 7 fold for me to break even. The head of the company get compensated insanely while the investor gets screwed.
  • Wow. Mr. Berlin's hard work has brought us back to 20 cents.